Insilico enters phase iii with the first ai-designed ipf drug

insilico medicine is progressing an ai-designed drug targeting idiopathic pulmonary fibrosis (ipf) into phase iii human trials. the treatment, which combats severe lung tissue scarring, has successfully cleared early safety evaluations to focus on late-stage efficacy validation. this advancement provides critical empirical data for the computational drug discovery sector, moving beyond theoretical potential to tangible medical applications. for the biotech industry, this development signals that generative ai platforms can successfully identify viable clinical candidates. upcoming results will determine if ai-derived molecules can match or exceed the efficacy of traditionally discovered therapies.